Similar articles

• Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.

  Burger DM. Burger DM. Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1151-60. doi: 10.1517/17425255.2010.513383. Expert Opin Drug Metab Toxicol. 2010. PMID: 20701552 Review.
• [Pharmacokinetics and interactions of raltegravir].

  Placeres Alsina MM, Tuset Creus M, Miró JM. Placeres Alsina MM, et al. Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:23-8. doi: 10.1016/s0213-005x(08)76569-8. Enferm Infecc Microbiol Clin. 2008. PMID: 19572422 Review. Spanish.
• Raltegravir: the first HIV integrase inhibitor.

  Cocohoba J, Dong BJ. Cocohoba J, et al. Clin Ther. 2008 Oct;30(10):1747-65. doi: 10.1016/j.clinthera.2008.10.012. Clin Ther. 2008. PMID: 19014832 Review.
• FDA notifications. Raltegravir indication extended for treatment-naive patients.

  [No authors listed] [No authors listed] AIDS Alert. 2009 Aug;24(8):93. AIDS Alert. 2009. PMID: 19705587 No abstract available.
• Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.

  Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Pescatore G, Scarpelli R, Stillmock K, Witmer MV, Rowley M. Summa V, et al. J Med Chem. 2008 Sep 25;51(18):5843-55. doi: 10.1021/jm800245z. J Med Chem. 2008. PMID: 18763751